Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secured access to crizotinib for genomically selected solid tumors
2013-000885-13Phase 2Completed
- Sponsor
- Unicancer
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in cancer, Nonhematologic neoplasms and Malignant Neoplasia, sponsored by Unicancer. Primary endpoint: Confirmed objective response rate per cohort. Started Apr 2013; status: completed.
02
Drugs
crizotinib
03
Conditions
cancerNonhematologic neoplasmsMalignant Neoplasia
Beyond the preview
Go deeper on 2013-000885-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000885-13.